Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- no (7)
Keywords
- CVID (1)
- European Society for Immunodeficiencies (ESID) (1)
- German PID-NET registry (1)
- IgG substitution therapy (1)
- PID prevalence (1)
- Red blood cell transfusion (1)
- agriculture (1)
- anaemia (1)
- elderly patients (1)
- habitat destruction (1)
Institute
- Medizin (3)
- Geschichtswissenschaften (1)
Plant diversity change for cities and their surroundings is well documented. For rural areas such studies are difficult as literature data are mostly insufficient. We reconstructed phytodiversity change in the Feldatal community (Germany, Hesse) by comparison of historical herbarium collections (1945–1976, Hans Hupke) with a recent floristic survey (2012). The study area is a rural area typical for Central Europe, dominated by agriculture and forestry and with a stable human population. Floristic diversity decreased (683 to 497 species; 31% of the total flora), principally by disappearance of species of unimproved grassland, fields and villages. The small number of newly documented species (33 spp.; 5% of total flora) comprises mostly naturalized ornamentals and salt tolerant species along roads. Plant diversity change of the last decades in rural landscapes in Central Europe was mainly dependent on the intensification of agriculture.
Die Fundmeldungen in Band 34 von Botanik und Naturschutz in Hessen stammen von: Dirk Bönsel, Martin De Jong, Klaus Dühr, Uta Engel, Benjamin Feller, Christian Feuring, Thomas Gregor, Arthur Händler, Karsten Horn, Diemut Klärner, Julia Kruse, Eric Martiné, Hasko Friedrich Nesemann, Kai Uwe Nierbauer, Uwe Raabe, Susanne Raehse, Felix Reischmann, Bernd Sauerwein, Petra Schmidt, Fabian Schrauth, Christof Nikolaus Schröder, Helmut Siebert, Michael Thieme, Otto Wacker und Rüdiger Wittig.
HDL, through sphingosine-1-phosphate (S1P), exerts direct cardioprotective effects on ischemic myocardium. It remains unclear whether other HDL-associated sphingophospholipids have similar effects. We therefore examined if HDL-associated sphingosylphosphorylcholine (SPC) reduces infarct size in a mouse model of transient myocardial ischemia/reperfusion. Intravenously administered SPC dose-dependently reduced infarct size after 30 minutes of myocardial ischemia and 24 hours reperfusion compared to controls. Infarct size was also reduced by postischemic, therapeutical administration of SPC. Immunohistochemistry revealed reduced polymorphonuclear neutrophil recruitment to the infarcted area after SPC treatment, and apoptosis was attenuated as measured by TUNEL. In vitro, SPC inhibited leukocyte adhesion to TNFα-activated endothelial cells and protected rat neonatal cardiomyocytes from apoptosis. S1P3 was identified as the lysophospholipid receptor mediating the cardioprotection by SPC, since its effect was completely absent in S1P3-deficient mice. We conclude that HDL-associated SPC directly protects against myocardial reperfusion injury in vivo via the S1P3 receptor.
Background: Perioperative anaemia leads to impaired oxygen supply with a risk of vital organ ischaemia. In healthy and fit individuals, anaemia can be compensated by several mechanisms. Elderly patients, however, have less compensatory mechanisms because of multiple co-morbidities and age-related decline of functional reserves. The purpose of the study is to evaluate whether elderly surgical patients may benefit from a liberal red blood cell (RBC) transfusion strategy compared to a restrictive transfusion strategy.
Methods: The LIBERAL Trial is a prospective, randomized, multicentre, controlled clinical phase IV trial randomising 2470 elderly (≥ 70 years) patients undergoing intermediate- or high-risk non-cardiac surgery. Registered patients will be randomised only if Haemoglobin (Hb) reaches ≤9 g/dl during surgery or within 3 days after surgery either to the LIBERAL group (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for the post-transfusion Hb level of 9–10.5 g/dl) or the RESTRICTIVE group (transfusion of a single RBC unit when Hb ≤ 7.5 g/dl with a target range for the post-transfusion Hb level of 7.5–9 g/dl). The intervention per patient will be followed until hospital discharge or up to 30 days after surgery, whichever occurs first. The primary efficacy outcome is defined as a composite of all-cause mortality, acute myocardial infarction, acute ischaemic stroke, acute kidney injury (stage III), acute mesenteric ischaemia and acute peripheral vascular ischaemia within 90 days after surgery. Infections requiring iv antibiotics with re-hospitalisation are assessed as important secondary endpoint. The primary endpoint will be analysed by logistic regression adjusting for age, cancer surgery (y/n), type of surgery (intermediate- or high-risk), and incorporating centres as random effect.
Discussion: The LIBERAL-Trial will evaluate whether a liberal transfusion strategy reduces the occurrence of major adverse events after non-cardiac surgery in the geriatric population compared to a restrictive strategy within 90 days after surgery.
Trial registration: ClinicalTrials.gov (identifier: NCT03369210).
Zum 60. Jahrestag des Kriegsendes von 1945 haben sich die ehemaligen Kriegsgegner europaweit im Großen und Ganzen einträchtig ihrer Opfer erinnert. Ein solch harmonisches Bild ist nicht selbstverständlich und auch nicht allerorts gegeben. Die neuerlichen Aufregungen rund um das geplante Zentrum gegen Vertreibung bestätigen, dass im erinnerungspolitischen Bereich zwischen der Bundesrepublik und ihren westeuropäischen Nachbarn noch immer mehr Gemeinsamkeiten bestehen als mit den Staaten Mittel- und Ostmitteleuropas. Denn über die Frage der Massenverbrechen der Nationalsozialisten hinaus ist noch der Streitherd von "Flucht und Vertreibung" zu klären. Die Deutsch-Tschechische und Deutsch-Slowakische Historikerkommission hat es sich zur Aufgabe gesetzt, die strittigen Punkte im deutsch-tschechischen bzw. deutsch-slowakischen Verhältnis der letzten anderthalb Jahrhunderte zu erforschen – ihr verdanken wir den vorliegenden Sammelband. Die Herausgeber folgen dabei dem Programm einer "Europäisierung des historischen Gedächtnisses", also der Erarbeitung einer Erinnerungslandschaft im europäischen Kontext. Durch weitere Aufklärung über die konkreten Entwicklungen und Schwierigkeiten innerhalb der Erinnerungsgeschichte der letzten 50 Jahre soll der Band dafür Grundlagen schaffen und "vorläufige Ergebnisse zu ausgewählten Forschungsthemen" bieten (S. 16f.). ...
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.